Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese zucker rats

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 560-569

  Mingorance, Carmen ^a   De Sotomayor, Maria Alvarez ^a   Marhuenda, Elisa ^a   Herrera, Maria Dolores ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

cannabinoids; COX; endothelium; iNOS; obese Zucker rats; obesity

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLCHOLINE; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; PROSTANOID; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME PHOSPHORYLATION; MOLECULAR INTERACTION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; VASCULAR RING; VASCULARIZATION; ZUCKER RAT;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; BODY WEIGHT; ENDOTHELIUM, VASCULAR; NITRIC OXIDE SYNTHASE TYPE II; NITROBENZENES; OBESITY; PHENYLEPHRINE; PIPERIDINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION; VASODILATOR AGENTS;

EID: 78650171814     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f7141a     Document Type: Article

References (50)

1. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al; RIO North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775.
2. Scheen AJ, Finer N, Hollander P, et al; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368: 1660-1672.
3. Van Gaal LF, Rissanen AM, Scheen AJ, et al; RIO Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397.
4. Kunos G, Osei-Hyiaman D, Bátkai S, et al. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci. 2009;30:1-7.
5. Ellis EF, Moore SF, Willoughby KA. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol. 1995;269:H1859-H1864.
6. Deutsch DG, Goligorsky MS, Schmid PC, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
7. Chaytor AT, Martin PE, Evans WH, et al. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol. 1999;520:539-550.
8. Ralevic V, Kendall DA, Randall MD, et al. Vanilloid receptors on capsaicin-sensitive nerves mediate relaxation to methanandamide in the rat isolated mesenteric bed. Br J Pharmacol. 2000;130:1483-1488.
9. Herradón E, Mart́in MI, López-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol. 2007;152:699-708. (Pubitemid 350034972)
10. Bátkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110:1996-2002.
11. Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol. 2010;105: 465-477.
12. Russell JC, Kelly SE, Diane A, et al. Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. Am J Physiol Gastrointest Liver Physiol. May 27, 2010 [Epub ahead of print].
13. Mingorance C, Alvarez de Sotomayor M, Jiménez-Palacios FJ, et al. Effects of the CB1 antagonist rimonabant on blood pressure and vascular reactivity of obese rats. Obesity (Silver Spring). 2009;17:1340-1347.
14. Chen P, Hu S, Yao J, et al. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res. 2005;69:28-35.
15. Wahn H, Wolf J, Kram F, et al. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol. 2005;289:H2491-H2496.
16. Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009; 16:94-112.
17. Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 2008;16:2081-2087.
18. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl). 2003;167:103-111.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-419.
20. Berrougui H, Alvarez de Sotomayor M, Pérez-Guerrero C, et al. Argan (Argania spinosa) oil lowers blood pressure and improves endothelial dysfunction in spontaneously hypertensive rats. Br J Nutr. 2004;92:921-929.
21. Granger DL, Taintor RR, Boockvar KS, et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996;268:142-151.
22. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol. 2008;286(Suppl 1):S66-S78.
23. André A, Gonthier MP. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol. June 9, 2010 [Epub ahead of print].
24. Du X, Edelstein D, Obici S, et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest. 2006;116:1071-1080.
25. Chinen I, Shimabukuro M, Yamakawa K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007; 148:160-165.
26. Sánchez A, Contreras C, Villaba N, et al. Altered arachidonic acid metabolism via COX-1 and COX-2 contributes to the endothelial dysfunction of penile arteries from obese Zucker rats. Br J Pharmacol. January 15, 2010 [Epub ahead of print].
27. 2 synthesis in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2009;296: R715-R721.
28. 2 production in the fructose hypertensive rat. Can J Physiol Pharmacol. 2007;85:422-429.
29. Xiang L, Dearman J, Abram SR, et al. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2008;294:H1658-H1666.
30. Schrör K. Cyclooxygenase-2-derived prostaglandin F2alpha: an endo-thelium-derived contractile factor acting independently of other endothe-lium-derived contractile factors via vascular thromboxane receptors. Circ Res. 2009;104:141-143.
31. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
32. Traupe T, Lang M, Goettsch W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002;20:2239-2245.
33. Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des. 2004;10:659-667.
34. Hattori Y, Nakano Y, Hattori S, et al. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett. 2008;582:1719-1724.
35. Malfitano AM, Laezza C, Pisanti S, et al. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol. 2008;153:1003-1010.
36. Mitchell MD, Sato TA, Wang A, et al. Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue-and CB1-receptor-specific mechanism. Am J Physiol Endocrinol Metab. 2008;294:E352-E356.
37. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocanna-binoids are involved in maintaining food intake. Nature. 2001;410: 822-825.
38. Thanos PK, Ramalhete RC, Michaelides M, et al. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse. 2008;62:637-642.
39. Wheeler-Jones CP. Regulation of endothelial prostacyclin synthesis by protease-activated receptors: mechanisms and significance. Pharmacol Rep. 2008;60:109-118.
40. Lépicier P, Bibeau-Poirier A, Lagneux C, et al. Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci. 2006;102:155-166.
41. Naik JS, Xiang L, Hodnett BL, et al. Alpha-adrenoceptor-mediated vasoconstriction is not involved in impaired functional vasodilation in the obese Zucker rat. Clin Exp Pharmacol Physiol. 2008;35:611-616.
42. Laight DW, Anggard EE, Carrier MJ. Investigation of basal endothelial function in the obese Zucker rat in vitro. Gen Pharmacol. 2000;35: 303-309.
43. Oltman CL, Richou LL, Davidson EP, et al. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol. 2006;291:H1780-H1787.
44. He Y, MacLeod KM. Modulation of noradrenaline-induced vasocon-striction in isolated perfused mesenteric arterial beds from obese Zucker rats in the presence and absence of insulin. Can J Physiol Pharmacol. 2002;80:171-179.
45. Subramanian R, MacLeod KM. Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol. 2003;477: 143-152.
46. Li R, Wang WQ, Zhang H, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab. 2007;293:E1703-E1708.
47. Cai XJ, Li CJ, Chen L, et al. A hypothesis: adiponectin mediates anti-atherosclerosis via adventitia-AMPK-iNOS pathway. Med Hypotheses. 2008;70:1044-1047.
48. Zhang P, Wang Y, Fan Y, et al. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:67-74.
49. Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation. 2009;119: 28-36.
50. Rajesh M, Mukhopadhyay P, Haskó G, et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and-independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol. 2010;160: 688-700.